Larry Wickerham, MD, and Charles E. Geyer, Jr., MD, FACP
Larry Wickerham, MD, and Charles E. Geyer, Jr., MD, FACP, take a closer look at the results from the NSABP B-36 and SOFT Trials.
Prudence Francis, MD, and Hope Rugo, MD
Prudence Francis, MD, of Peter MacCallum Cancer Centre, and Hope Rugo, MD, of the University of California, San Francisco, discuss data from abstract S3-08, "Randomized comparison of adjuvant tamoxifen plus ovarian function suppression vs tamoxifen in premenopausal women with hormone receptor–positive early breast cancer: Analysis of the SOFT trial."
Matthew J. Ellis, MD, PhD, and Harold J. Burstein, MD, PhD
Matthew J. Ellis, MD, PhD, of the Baylor College of Medicine discusses with Harold J. Burstein, MD, PhD, of the Dana-Farber Cancer Institute genome-directed therapeutics for endocrine therapy-resistant estrogen receptor-positive breast cancer.
Harold J Burstein MD PhD and Lisa A Carey MD
Harold J. Burstein, MD, PhD, of the Dana-Farber Cancer Institute and Lisa Carey, MD, of the UNC Lineberger Comprehensive Cancer Center, discuss:
- The TNT trial comparing docetaxel to carboplatin
- The CALGB trial on response rates after neoadjuvant chemo with or without carboplatin or bevacizumab
- Pembrolizumab in a phase Ib study
